IRadimed Corporation (IRMD) Sets 52-Week High; Strong Momentum for Holders

June 29, 2018 - By Carrie Sands

IRadimed Corporation (NASDAQ:IRMD) Logo

Investors sentiment decreased to 0.93 in 2018 Q1. Its down 1.64, from 2.57 in 2017Q4. It is negative, as 4 investors sold IRadimed Corporation shares while 10 reduced holdings. 4 funds opened positions while 9 raised stakes. 1.77 million shares or 9.50% more from 1.61 million shares in 2017Q4 were reported.
Barclays Public Limited, United Kingdom-based fund reported 14 shares. 500 were accumulated by Wells Fargo And Mn. 43,493 were accumulated by Blackrock. Granite Investment Prns, California-based fund reported 35,633 shares. Ameriprise Financial owns 470,382 shares for 0% of their portfolio. Moreover, Mondrian Invest Prtnrs has 0.09% invested in IRadimed Corporation (NASDAQ:IRMD). 29,426 are owned by Eam Invsts Ltd. Spark Inv Mngmt Ltd Limited Liability Company accumulated 30,900 shares. Morgan Stanley invested in 19,969 shares. Renaissance Ltd Com invested 0% in IRadimed Corporation (NASDAQ:IRMD). Bank & Trust Of Mellon holds 0% of its portfolio in IRadimed Corporation (NASDAQ:IRMD) for 15,432 shares. 112,529 were reported by Cadence Mgmt Ltd Liability. Bancshares Of America De owns 387 shares. Deutsche Bancorporation Ag, Germany-based fund reported 16,616 shares. Connors Investor Inc owns 33,000 shares.

Since March 15, 2018, it had 1 insider buy, and 4 sales for $1.18 million activity. $415,026 worth of IRadimed Corporation (NASDAQ:IRMD) was sold by Waldman Louis S. on Thursday, March 15. On Wednesday, May 2 the insider ALLEN MONTY K sold $34,068. Susi Roger E. also bought $13,850 worth of IRadimed Corporation (NASDAQ:IRMD) on Friday, March 16.

The stock of IRadimed Corporation (NASDAQ:IRMD) hit a new 52-week high and has $20.86 target or 3.00 % above today’s $20.25 share price. The 6 months bullish chart indicates low risk for the $215.79M company. The 1-year high was reported on Jun, 29 by Barchart.com. If the $20.86 price target is reached, the company will be worth $6.47 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.25% or $0.25 during the last trading session, reaching $20.25. About 19,638 shares traded. IRadimed Corporation (NASDAQ:IRMD) has risen 122.29% since June 29, 2017 and is uptrending. It has outperformed by 109.72% the S&P500.

Analysts await IRadimed Corporation (NASDAQ:IRMD) to report earnings on July, 27. They expect $0.08 earnings per share, up 166.67 % or $0.05 from last year’s $0.03 per share. IRMD’s profit will be $852,504 for 63.28 P/E if the $0.08 EPS becomes a reality. After $0.07 actual earnings per share reported by IRadimed Corporation for the previous quarter, Wall Street now forecasts 14.29 % EPS growth.

Iradimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging compatible products, and related accessories and services in the United States and internationally. The company has market cap of $215.79 million. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. It has a 160.71 P/E ratio. The firm also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories; iMagox MRI pulse oximeter; and iMagox MRI oximeter remote and display products.

IRadimed Corporation (NASDAQ:IRMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.